Melanie Kelly

Dr. Melanie Kelly (she/her) is a Professor in the Departments of Pharmacology, Ophthalmology & Visual Sci., Faculty of Medicine, Dalhousie University. Prof. Kelly is a Director for the Canadian Consortium for Investigation of Cannabinoids (CCIC) and President and Chief Scientific Officer for Altheda Wellness Innovation, a Canadian company operating in the natural products and health tech space. Professor Kelly has extensive research and leadership experience in academia as well as industry and is considered a key knowledge opinion leader in cannabinoid and phytochemical drug development. Her primary research expertise is in translational and ocular pharmacology. She has been funded for her research on the endocannabinoid system and lipid signaling by multiple international and national funding agencies and has successfully translated her team’s research findings into novel therapeutics to improve health outcomes in age-related disease. Professor Kelly has over 135 peer reviewed publications and multiple patents for development and use of cannabinoid drugs and natural products.